title: Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy.
abstract: The aims of the study were to characterize the magnitude of clearance changes during pregnancy for multiple antiepileptic drugs (AEDs) and to assess seizure frequency and factors increasing seizure risk in pregnant women with epilepsy. A retrospective analysis was performed for 115 pregnancies in 95 women with epilepsy followed at the Emory Epilepsy Center between 1999 and 2012. Antiepileptic drug blood levels (ABLs) obtained during routine clinical practice were used to calculate AED clearance at multiple points during pregnancy. Antiepileptic drug doses and seizure activity were also recorded. The data were analyzed for changes in clearance and dose across pregnancy and for an association between ABL and changes in seizure frequency. Significant changes in clearance during pregnancy were observed for lamotrigine (p<0.001) and levetiracetam (p<0.006). Average peak clearance increased by 191% for lamotrigine and 207% for levetiracetam from nonpregnant baseline. Marked variance was present across individual women and also across repeat pregnancies in individual women. Despite increased AED dose across most AEDs, seizures increased in 38.4% of patients during pregnancy. Seizure deterioration was significantly more likely in patients with seizures in the 12 months prior to conception (p<0.001) and those with localization-related epilepsy (p=0.005). When ABL fell >35% from preconception baseline, seizures worsened significantly during the second trimester when controlling for seizure occurrence in the year prior to conception. Substantial pharmacokinetic changes during pregnancy occur with multiple AEDs and may increase seizure risk. Monitoring of AED serum concentrations with dose adjustment is recommended in pregnant women with epilepsy. Further studies are needed for many AEDs.
authors.affiliation: Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: T L
authors.initials: TL
authors.lastname: Reisinger
authors.forename: M
authors.initials: M
authors.lastname: Newman
authors.forename: D W
authors.initials: DW
authors.lastname: Loring
authors.forename: P B
authors.initials: PB
authors.lastname: Pennell
authors.forename: K J
authors.initials: KJ
authors.lastname: Meador
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011264:Pregnancy Trimesters / Q000097:blood / Q000187:drug effects; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000927:Anticonvulsants
keywords: ABL; AED; AED blood level; Antiepileptic drugs; CBZ; Cl; Clearance; ESM; Epilepsy; LEV; LTG; OXC; PHT; Pharmacokinetics; Pregnancy; Seizure frequency; TPM; VPA; ZNS; antiepileptic drug; carbamazepine; clearance; ethosuximide; lamotrigine; levetiracetam; oxcarbazepine; phenytoin; topiramate; valproate; zonisamide
references.citation: Neurology. 2000 Aug 22;55(4):588-91
references.pmid: 10953201
references.citation: Epilepsia. 2013 Mar;54(3):405-14
references.pmid: 23360413
references.citation: Acta Neurol Scand. 2004 Jan;109(1):9-13
references.pmid: 14653845
references.citation: Epilepsia. 2009 May;50(5):1229-36
references.pmid: 19496807
references.citation: Neurology. 2012 May 22;78(21):1692-9
references.pmid: 22551726
references.citation: Epilepsy Res. 2005 Mar-Apr;64(1-2):1-11
references.pmid: 15823510
references.citation: Epilepsy Res. 2009 Apr;84(2-3):245-9
references.pmid: 19231139
references.citation: Neurology. 2004 Jan 27;62(2):292-5
references.pmid: 14745072
references.citation: Seizure. 2008 Mar;17(2):192-8
references.pmid: 18180176
references.citation: Epilepsy Res. 2002 May;49(3):211-7
references.pmid: 12076842
references.citation: Neurology. 2009 Jul 14;73(2):142-9
references.pmid: 19398680
references.citation: Br J Clin Pharmacol. 1984 Nov;18(5):671-7
references.pmid: 6508976
references.citation: J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):193-8
references.pmid: 16157661
references.citation: Neurology. 2006 Feb 14;66(3):354-60
references.pmid: 16382034
references.citation: Rev Neurol Dis. 2011;8(1-2):16-22
references.pmid: 21769067
references.citation: Epilepsy Res. 2008 Sep;81(1):1-13
references.pmid: 18565732
references.citation: Neurology. 2008 May 27;70(22 Pt 2):2130-6
references.pmid: 18046009
references.citation: Neurology. 2002 Jul 23;59(2):251-5
references.pmid: 12136066
references.citation: Epilepsy Res. 2005 Jul;65(3):185-8
references.pmid: 16084694
references.citation: Lancet Neurol. 2011 Jul;10(7):609-17
references.pmid: 21652013
references.citation: Drug Saf. 2010 Jan 1;33(1):73-9
references.pmid: 20000869
references.citation: Epilepsia. 2007 Jun;48(6):1111-6
references.pmid: 17381438
references.citation: Curr Pharm Biotechnol. 2011 May;12(5):781-8
references.pmid: 21342118
references.citation: Ann Pharmacother. 2008 Jul;42(7):1139-41
references.pmid: 18577760
references.citation: Epilepsia. 1994 Jan-Feb;35(1):122-30
references.pmid: 8112234
references.citation: Neurology. 2003 Sep 1;61(6 Suppl 2):S35-42
references.pmid: 14504308
references.citation: Curr Opin Neurol. 2009 Apr;22(2):157-61
references.pmid: 19532039